Healthcare / Diagnostics & ResearchKOSDAQ
$4625.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-3.5B · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$67.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.8%
↓Gross Margin
25.0%
↓Debt/Equity
0.42
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.8%
FCF CAGR
—
FCF margin
-18.3%
FCF / Net income
1.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $22.34B · net income $-2.50B · FCF $-4.10B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $22.34B | $22.34B | $19.64B | $17.37B | $16.01B |
| Net Income | $-2.50B | $-2.50B | $-2.36B | $-2.44B | $-2.04B |
| EBITDA | $-321.0M | $-321.0M | $-198.1M | $-526.1M | $-570.7M |
| EPS | -170.00 | -170.00 | -161.00 | -166.00 | -140.00 |
| Gross Margin | 25.0% | 25.0% | 24.9% | 24.2% | 23.2% |
| Operating Margin | -10.8% | -10.8% | -12.5% | -15.1% | -13.7% |
| Net Margin | -11.2% | -11.2% | -12.0% | -14.0% | -12.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.42 | 0.42 | 0.40 | 0.40 | 0.27 |
| Current Ratio | 1.17 | 1.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.10B | $-4.10B | $-2.33B | $-3.46B | $-7.00B |
| Returns | |||||
| ROE | -9.8% | -9.8% | -8.6% | -9.7% | -7.0% |
| Valuation | |||||
| P/B | 2.68 | 2.68 | 2.54 | 4.11 | 3.45 |
| Growth & Yield | |||||
| Revenue Growth | 13.8% | 13.8% | 13.0% | 8.5% | — |
| EPS Growth | -5.6% | -5.6% | 3.0% | -18.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-161.00 → -170.00
Residual
-10.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.